Arrowhead Pharmaceuticals, Inc. (ARWR) Expected to Announce Quarterly Sales of $7.32 Million
Analysts predict that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will report $7.32 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from $6.63 million to $8.00 million. Arrowhead Pharmaceuticals reported sales of $30,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 24,300%. The business is scheduled to issue its next earnings results on Wednesday, December 13th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $7.32 million for the current year, with estimates ranging from $29.32 million to $35.00 million. For the next fiscal year, analysts expect that the firm will report sales of $9.93 million per share, with estimates ranging from $6.30 million to $15.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Arrowhead Pharmaceuticals.
A number of research analysts recently commented on the company. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 25th. William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Piper Jaffray Companies reissued a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $2.00.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $3.68 on Friday. Arrowhead Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $5.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.84 and a quick ratio of 3.84.
Several institutional investors have recently bought and sold shares of ARWR. ING Groep NV purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $3,500,000. LMR Partners LLP purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $467,000. Wells Fargo & Company MN increased its position in shares of Arrowhead Pharmaceuticals by 144.8% during the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after acquiring an additional 88,933 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Arrowhead Pharmaceuticals by 414.7% during the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 53,500 shares during the period. Finally, Virtu KCG Holdings LLC increased its position in shares of Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 53,215 shares during the period. 20.62% of the stock is currently owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.